TY - JOUR
T1 - MicroRNAs and prostate cancer
T2 - From preclinical research to translational oncology
AU - Maugeri-Saccà, Marcello
AU - Coppola, Valeria
AU - Bonci, Désirée
AU - De Maria, Ruggero
PY - 2012/5
Y1 - 2012/5
N2 - The management of prostate cancer patients is rapidly changing. The extended survival seen in randomized phase III trials with new molecules has significantly enriched the therapeutic armamentarium, and ongoing clinical trials are assessing whether the integration of these active drugs within established therapeutic regimens results in a further benefit for patients. This complex scenario is raising the need for the identification and validation of biomarkers able to drive the decision-making process during the course of the disease. Compelling evidence has documented the role of microRNAs in cancer biology, and their multifaceted biological activity makes them an attractive candidate as diagnostic, prognostic, and predictive biomarkers. This review summarizes the current knowledge about microRNA deregulation in prostate cancer, how these molecules have been investigated in the clinical setting, and strategies investigators should consider for sharpening their potential.
AB - The management of prostate cancer patients is rapidly changing. The extended survival seen in randomized phase III trials with new molecules has significantly enriched the therapeutic armamentarium, and ongoing clinical trials are assessing whether the integration of these active drugs within established therapeutic regimens results in a further benefit for patients. This complex scenario is raising the need for the identification and validation of biomarkers able to drive the decision-making process during the course of the disease. Compelling evidence has documented the role of microRNAs in cancer biology, and their multifaceted biological activity makes them an attractive candidate as diagnostic, prognostic, and predictive biomarkers. This review summarizes the current knowledge about microRNA deregulation in prostate cancer, how these molecules have been investigated in the clinical setting, and strategies investigators should consider for sharpening their potential.
KW - biomarkers
KW - microRNAs
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84862186491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862186491&partnerID=8YFLogxK
U2 - 10.1097/PPO.0b013e318258b5b6
DO - 10.1097/PPO.0b013e318258b5b6
M3 - Article
C2 - 22647362
AN - SCOPUS:84862186491
VL - 18
SP - 253
EP - 261
JO - Cancer Journal from Scientific American
JF - Cancer Journal from Scientific American
SN - 1528-9117
IS - 3
ER -